Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 14, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis

aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary Fibrosis
May 07, 2025 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update

aTyr Pharma Announces First Quarter 2025 Results and Provides Corporate Update
April 29, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025

aTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025
April 03, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Participate in April Investor Conferences

aTyr Pharma to Participate in April Investor Conferences
March 27, 2025 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

aTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 26, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise

aTyr Pharma Announces the Appointment of Dalia R. Rayes as Head of Commercial, Global Efzofitimod Franchise
March 13, 2025 16:01 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update

aTyr Pharma Announces Fourth Quarter and Full Year 2024 Results and Provides Corporate Update
March 12, 2025 16:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine

aTyr Pharma Announces Publication Demonstrating Efzofitimod’s Immunomodulatory Activity in Science Translational Medicine
March 06, 2025 16:02 ET | Source: aTyr Pharma, Inc.

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis

aTyr Pharma Announces Fourth Positive DSMB Review for Efzofitimod in Phase 3 EFZO-FIT™ Study in Pulmonary Sarcoidosis
March 04, 2025 08:00 ET | Source: aTyr Pharma, Inc.

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

aTyr Pharma to Webcast Conference Call Reporting Fourth Quarter and Full Year End 2024 Financial Results

Next Page keyboard_arrow_right